March 29, 2022 10:53 AM EDT

Antares Pharma wins FDA OK for oral testosterone treatment; Eye-focused biotech reports PhIII data for pupil dilation drug

Paul Schloesser

Associate Editor

Antares Pharma has nabbed another FDA approval, and the company’s second involving testosterone.
The New Jersey pharma announced the company’s approval …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Antares Pharma wins FDA OK for oral testosterone treatment; Eye-focused biotech reports PhIII data for pupil dilation drug

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Antares Phar­ma wins FDA OK for oral testos­terone treat­ment; Eye-fo­cused biotech re­ports PhI­II da­ta for pupil di­la­tion drug

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Antares Pharma wins FDA OK for oral testosterone treatment; Eye-focused biotech reports PhIII data for pupil dilation drug